Will HCP's Endeavors To Revamp Portfolio Be Sufficient?
Zacks Investment Research | Jun 19, 2018 09:46PM ET
HCP Inc. (NYSE:HCP) has undertaken portfolio-repositioning measures in a bid to improve the quality of its senior housing portfolio and lower the concentration of Brookdale Senior Living Inc. Earlier in this month, HCP provided an update about such efforts and it seems right on track to achieve its target.
In fact, over time, with diligent measures, the company aims at having more than half of its business comprising specialty office segments of medical office and life science, and lower senior housing concentration to around 40%. The focus on having a diversified private pay portfolio is likely to drive long-term growth.
Nevertheless, the softness in the seniors housing market fundamentals amid new supply is anticipated to thwart the company’s pricing power. Further, the hike in interest rate and stiff competition remain concerns for the company.
Per its recent update, HCP has reaped $332 million of proceeds through the completion of the disposition of its residual investment in the RIDEA II senior housing joint venture (JV) to an investor group led by Columbia Pacific Advisors, LLC. Notably, this JV owned 49 communities and 46 of them were managed by Brookdale.
Regarding Brookdale 25 asset sales, the company has already accomplished the disposition of five communities for $32 million and is under contract to sell another 15 communities for $98 million. The remaining five assets are expected to be either sold or transitioned this year too.
Further, HCP is focused on making acquisitions to enhance its overall portfolio mix. The company acquired Hayden Research Campus in the Boston life-science market in December 2017 and is experiencing strong leasing velocity. Moreover, in March 2018, the company acquired development rights at Hayden for $21 million and its planned 214,000-square-foot Class A development is expected to improve the company’s scale in this leading life science market. Also, the company started Phase I of Sierra Point, which marks its next key life-science development in the South San Francisco market.
In fact, increasing longevity of the aging U.S. population, along with growth opportunities related to biopharma drug development, have promoted life science and medical-market fundamentals. The trend is expected to continue in the upcoming years, giving significant impetus for growth to HCP.
Moreover, national healthcare expenditure is expected to rise in the future and as senior citizens constitute the major customer base of healthcare services – they end up spending more on healthcare services compared with the average population. Hence, with an expectation of rising senior citizens’ population in the years ahead, we believe that HCP has a strong upside potential, being well poised to capitalize on this expenditure trend of senior citizens on healthcare services.
Get The News You Want
However, softness in the seniors housing fundamentals is likely to continue in the upcoming quarters, amid rise in new supply in the market. This is anticipated to adversely affect the company’s pricing power and occupancy level. In addition, the cut-throat competitive market makes it more challenging for the company to increase its rent and occupancy level. The competition also makes it hard to identify and successfully capitalize on acquisition opportunities to meet the company’s objectives.
Moreover, the company is currently focusing on lowering its Brookdale-portfolio concentration. The move involves strategic efforts, including selling of considerable part of its portfolio and using the proceeds in debt repayment. Although such efforts are a strategic fit for the long term, the dilutive impact on earnings in the near term from the sale of assets is unavoidable.
Amid these, shares of this Zacks Rank #3 (Hold) company have underperformed its Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.